Dactinomycin

DRACPC ID  DRACPC0076

Active Ingredients   Dactinomycin

Description  A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. This compound belongs to the class of organic compounds known as cyclic depsipeptides. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. 

Synonyms  Actinomycin A IV; Actinomycin C1; ACTINOMYCIN D; Actinomycin I1; Actinomycin IV; Actinomycin X 1; Actinomycin-[thr-val-pro-sar-meval]; Cosmegen; Dactinomycine; Dactinomycin; DACT; Lyovac Cosmegen; Meractinomycin

Type  Small Molecule

Disease  Wilms' tumor, Childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, Nonseminomatous testicular cancer 

Classification

  

Antibiotic Peptide and derivative Cyclic

Structure Information


Molecular Formula  C62H86N12O16

Molecular Weight  1255.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  N1,N9-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

InChI  InChI=1S/C66H94N12O16/c1-17-21-37-25-26-38(57(82)71-48-35(11)92-65(90)52(33(7)8)75(15)42(79)29-73(13)61(86)40-23-19-27-77(40)63(88)46(31(3)4)69-59(48)84)50-55(37)94-56-39(22-18-2)54(81)45(67)44(51(56)68-50)58(83)72-49-36(12)93-66(91)53(34(9)10)76(16)43(80)30-74(14)62(87)41-24-20-28-78(41)64(89)47(32(5)6)70-60(49)85/h25-26,31-36,40-41,46-49,52-53H,17-24,27-30,67H2,1-16H3,(H,69,84)(H,70,85)(H,71,82)(H,72,83)/t35-,36-,40+,41+,46-,47-,48+,49+,52+,53+/m1/s1

InChI_Key LJSAZAHIIMMOOW-PCHXSYTBSA-N

SMILES  CC(C)[C@@H](NC([C@@H](NC(C1=C(N=C(C2=C3CCC)C(C(N[C@@H]([C@H](O4)C)C(N[C@@H](C(N5CCC[C@@]5([H])C(N(C)CC(N(C)[C@@H](C(C)C)C4=O)=O)=O)=O)C(C)C)=O)=O)=C(N)C3=O)C(O2)=C(CCC)C=C1)=O)[C@H](O6)C)=O)C(N7CCC[C@@]7([H])C(N(C)CC(N(C)[C@@H](C(C)C)C6=O)=O)=O)=O

External Codes


PubChem CID  457193

DrugBank Accession Number  DB00970

NCI Thesaurus Code  C412  

UNII  1CC1JFE158   GSRS

CAS  50-76-0



Drug approval


Drug indication
    For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Dactinomycin 0.5mg/vial Injectable; Injection Hikma Discontinued ANDA: 090304 2010
Dactinomycin 0.5mg/vial Injectable; Injection Am Regent Discontinued ANDA: 202562 2013
Dactinomycin 0.5mg/vial Injectable; Injection Eugia Pharma Prescription ANDA: 203385 2017
Dactinomycin 0.5mg/vial Injectable; Injection Xgen Pharms Prescription ANDA: 203999 2019
Dactinomycin 0.5mg/vial Injectable; Injection Hisun Pharm Hangzhou Prescription ANDA: 207232 2019
Dactinomycin 0.5mg/vial Injectable; Injection Meitheal Prescription ANDA: 213463 2020
Cosmegen 0.5mg/vial Injectable; Injection Recordati Rare Prescription NDA: 213463 1964
Cosmegen 0.5 mg / vial Powder For Solution Recordati Rare Diseases Canada Inc Prescription DIN: 00213071 1963

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01323517 A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity Melanoma Phase 2 Treatment
NCT00003688 Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia Gestational Trophoblastic Tumor Phase 2 Treatment
NCT00075582 Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma Adult Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma Phase 3 Treatment
NCT00245089 Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma Sarcoma Phase 2 Treatment
NCT00352534 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Stage I Wilms Tumor; Stage II Wilms Tumor; Stage III Wilms Tumor Phase 3 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.